Clinical management of β-thalassemia major

Seminars in Hematology

Volumn 38, Issue 4, 2001, Pages 350-359

  Wonke, Beatrix ^a  

^a WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFEROXAMINE; GROWTH HORMONE; IRON CHELATING AGENT; MACROGOL; RECOMBINANT ALPHA2B INTERFERON; SEX HORMONE; THYROXINE;

BACTERIAL INFECTION; BETA THALASSEMIA; BLOOD TRANSFUSION; CELIAC DISEASE; EARLY DIAGNOSIS; ENDOCRINE DISEASE; GALLSTONE; HEART DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSPLENISM; IRON OVERLOAD; LEG ULCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL MATURATION; YERSINIA;

EID: 0034773091     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90029-0     Document Type: Article

References (66)

1. Cardiac iron deposition is not predicted by conventional markers of iron overload in homozygous β-thalassemia
2. Relationship of myocardial iron overload to right and left ventricular function in β-thalassemia
3. Bone pain in thalassemia. Assessment of DEXA and MRI findings
4. Antibodies to hepatitis C virus in thalassemia
5. The contribution of hypogonadism to the development of osteoporosis in thalassemia major; new therapeutic approaches
6. Differential iron deposition in the anterior pituitary and liver in homozygous β thalassemia; prediction of gonadal failure by magnetic resonance imaging
7. Transforming growth factor-β1 gene polymorphism, bone turnover and bone mass in Italian postmenopausal women
8. Role of transforming growth factor-beta in bone remodelling
9. Cholelithiasis in children with thalassemia major. An ultrasonographic study
10. British Committee for Standards in Haematology. Blood Transfusion Task Force: Guidelines on the clinical use of leucocyte-depleted blood components
11. Iron in the heart. Etiology and clinical significance
12. Effects of calcitonin therapy on osteoporosis in patients with thalassemia
13. Genotype-phenotype correlations in β thalassemia
14. A moderate transfusion regimen may reduce iron loading in β thalassemia major without producing excessive expansion of erythropoiesis
15. Relationship between transfusion regimen and suppression of erythropoiesis in β thalassemia major
16. Effect of iron overload on the response to recombinant interferon-alpha treatment in transfusion dependent patients with thalassemia major and chronic hepatitis
17. Incidence of AIDS in HIV- 1 infected thalassemia patients
18. Growth hormone secretion in thalassemia patients with short stature
19. Multicentre study on prevalence of endocrine complications in thalassemia major
20. Induction of spermatogenesis in thalassemia
21. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells
22. Cholelithiasis in thalassemia major
23. Alpha interferon in the treatment of chronic hepatitis C virus in multiply transfused patients with thalassemia major
24. European Association for the Study of the Liver International Consensus Conference on hepatitis C. Consensus Statement
25. Prophylactic cholecystectomy during splenectomy for beta thalassemia homozygous in Greece
26. Early left ventricular dysfunction and chelation therapy in thalassemia major
27. Reduced bone density and osteoporosis associated with polymorphic Sp 1 binding site in collagen type a 1 gene
28. Effect of a thalassemia trait and enhanced γ chain production on disease severity in β thalassemia major and intermedia
29. High prevalence of low bone mass in thalassemia major
30. Fertility in thalassemia: The Greek experience
31. Lifetime treatment cost of β thalassemia major
32. Ultrastructural pathology of the heart in patients with beta thalassemia major
33. Glucose disturbances and regulation with glibenclamide in thalassemia
34. Cardiac iron overload in thalassemic patients. An endomyocardial biopsy study
35. Human immunodeficiency virus infection in multi-transfused patients with thalassemia major
36. Survival in beta thalassemia major in the United Kingdom: Data from the UK Thalassemia Register
37. Red cells by apheresis
38. Osteoporosis in β thalassemia major patients: Analysis of the genetic background
39. Impaired growth hormone response to growth hormone releasing hormone in thalassemia major
40. Hypertransfusion regimen in patients with Cooley's anemia
41. Double erythroapheresis improves quality and safety of hemotherapy in multitransfused patients with thalassemia
42. Bone mineral metabolism in adults with β thalassemia major and intermedia
43. New approaches to the transfusion management of thalassemia
44. Bone disease in children with homozygous β thalassemia
45. Short stature and failure of pubertal development in thalassemia major; evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotrophin secretion
46. Primary hypothyroidism and low T 3 syndrome in thalassemia major
47. Histochemical studies of the myocardium and conduction system in acquired iron storage disease
48. Expanding role of bisphosphonate therapy in children
49. Assessment of hematologic effects of ribavirin in humans
50. Fertility in female patients with thalassemia
51. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassemic patients
52. Pregnancy management and outcomes in women with thalassemia major
53. Re-assessment of the value of splenectomy in thalassemia major
54. Bone resorption is increased in young adults with thalassemia major
55. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major
56. Cardiac care for thalassemia patients at University College Hospital, London
57. Measured and predicted bone mineral content in healthy boys and girls aged 6-18 years: Adjustment for body size and puberty
58. Leucocyte depletion of the blood supply - How will patients benefit?
59. Bone disease in β thalassemia major
60. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassernia major
61. Antibody to hepatitis C virus in multiply transfused patients with thalassemia major
62. Assessment of fracture risks and its application to screening for post-menopausal osteoporosis
63. Survival and causes of death in thalassemia major